We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Alnylam Pharmaceuticals (ALNY - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.21 per share, reflecting an increase of 80.9% compared to the same period last year. Revenues are forecasted to be $570.11 million, representing a year-over-year increase of 29.7%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenues- Product revenues, net' at $437.81 million. The estimate suggests a change of +26.4% year over year.
The consensus estimate for 'Revenues- Royalty revenue' stands at $27.14 million. The estimate indicates a year-over-year change of +59.4%.
According to the collective judgment of analysts, 'Revenues- Net revenues from research collaborators' should come in at $106.14 million. The estimate suggests a change of +38.9% year over year.
The combined assessment of analysts suggests that 'Net Product Revenues- Oxlumo' will likely reach $44.79 million. The estimate indicates a change of +36.8% from the prior-year quarter.
Analysts predict that the 'Net Product Revenues- Givlaari' will reach $68.78 million. The estimate indicates a year-over-year change of +16%.
Analysts' assessment points toward 'Net Product Revenues- Amvuttra' reaching $280.22 million. The estimate points to a change of +59.9% from the year-ago quarter.
The consensus among analysts is that 'Net Product Revenues- Onpattro' will reach $47.70 million. The estimate points to a change of -39.6% from the year-ago quarter.
Shares of Alnylam have demonstrated returns of +16.1% over the past month compared to the Zacks S&P 500 composite's +2.1% change. With a Zacks Rank #2 (Buy), ALNY is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
In its upcoming report, Alnylam Pharmaceuticals (ALNY - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.21 per share, reflecting an increase of 80.9% compared to the same period last year. Revenues are forecasted to be $570.11 million, representing a year-over-year increase of 29.7%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenues- Product revenues, net' at $437.81 million. The estimate suggests a change of +26.4% year over year.
The consensus estimate for 'Revenues- Royalty revenue' stands at $27.14 million. The estimate indicates a year-over-year change of +59.4%.
According to the collective judgment of analysts, 'Revenues- Net revenues from research collaborators' should come in at $106.14 million. The estimate suggests a change of +38.9% year over year.
The combined assessment of analysts suggests that 'Net Product Revenues- Oxlumo' will likely reach $44.79 million. The estimate indicates a change of +36.8% from the prior-year quarter.
Analysts predict that the 'Net Product Revenues- Givlaari' will reach $68.78 million. The estimate indicates a year-over-year change of +16%.
Analysts' assessment points toward 'Net Product Revenues- Amvuttra' reaching $280.22 million. The estimate points to a change of +59.9% from the year-ago quarter.
The consensus among analysts is that 'Net Product Revenues- Onpattro' will reach $47.70 million. The estimate points to a change of -39.6% from the year-ago quarter.
View all Key Company Metrics for Alnylam here>>>
Shares of Alnylam have demonstrated returns of +16.1% over the past month compared to the Zacks S&P 500 composite's +2.1% change. With a Zacks Rank #2 (Buy), ALNY is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>